A post-incorporation study on the use of palivizumab in the Brazilian public health system

Abstract

This is an open-access article distributed under the terms of the Creative Commons Attribution License.

Respiratory Syncytial Virus: Knowledge, Attitudes and Beliefs of General Practitioners from North-Eastern Italy (2021)

“…On the other hand, RSV vaccines are commercially unavailable [ 1 , 3 , 9 , 12 , 13 ], and preventive interventions are limited to monoclonal antibodies (mAb) [ 14 , 15 , 16 ]. Despite their efficacy in avoiding hospitalizations and long-term sequelae, their use is forcibly limited to some high-risk groups (i.e., prematurely-born infants under 6 months of age, and children with certain comorbidities under 2 years of age during the RSV season) [ 9 , 17 , 18 , 19 , 20 , 21 ].…”

Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians

“…Collectively, such features could explain the favorable attitude towards an intervention that is perceived as both accessible and effective, as well as the substantial lack of familiarity with mAb in the clinical practice. Indeed, official recommendations for palivizumab are quite restrictive [ 10 , 16 , 27 , 29 , 30 , 31 ], prioritizing or even limiting the use of this drug on very selective groups of infants [ 34 ], and only after the conclusion of this survey’s extended half-life have mAb, such as nirsevimab, been available in the EU [ 35 , 36 , 38 ]. As nirsevimab’s easier and potentially more affordable handling could radically increase the share of targeted infants, it is quite reasonable that also the familiarity of clinical practitioners could increase in the next years [ 4 , 11 , 35 , 36 , 37 , 38 , 82 ].…”

“…Despite its proven efficacy, this is a relatively expensive medication, as the cost for a 100-mg vial usually ranges from 904$ to 1866$ [ 4 , 5 , 24 , 25 , 26 , 28 ]. Moreover, guideline indications have become increasingly restrictive, and a palivizumab license is currently limited to some high-risk groups [ 10 , 16 , 27 , 29 , 30 , 31 ], including: (a) infants born at ≤ 35 weeks of Gestational Age (wGA); (b) children < 2 years of age affected by chronic lung disease of prematurity (CLD); and (c) children < 2 years of age affected by hemodynamically significant congenital heart disease (CHD) [ 32 , 33 , 34 ]. Nevertheless, not only have recommendations changed over the years, but stronger limitations have been issued depending on countries’ public health policies [ 25 , 26 , 28 ].…”

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita

“…Batista et al 94 , en el estudio de cohorte retrospectivo con una muestra de 129 niños reclutados en el Hospital Materno-infantil Presidente Vargas (HMIPV) y en el Hospital de Clínicas de Porto Alegre (HCPA), ambos ubicados en la ciudad de Porto Alegre, en el Sur de Brasil, evaluaron a efectividad de un programa público de profilaxis con palivizumab sobre la incidencia de hospitalizaciones por infecciones del tracto respiratorio inferior y VSR en niños con alto riesgo de infecciones graves por VSR. La muestra incluía menores de dos años con cardiopatías congénitas hemodinámicamente significativas.…”